NorthStar Medical Radioisotopes has expanded its strategic collaboration with Curadh, the organization announced today.

According to a release, under the new agreement, NorthStar will manufacture and distribute patient doses for ongoing Curadh Ac-225 clinical studies and provide Ac-225 for commercial use upon NorthStar’s submission of a Type II Drug Master File (DMF) to the Food and Drug Administration.

“This collaboration leverages NorthStar’s advanced technology and development and manufacturing expertise to advance Curadh’s innovative radiopharmaceutical candidates to benefit patients with cancer,” NorthStar Medical Radioisotopes CEO Frank Scholz said in a statement.

NorthStar also will manufacture and distribute patient doses of Curadh diagnostic and therapeutic isotopes of future interest.

Financial details were not disclosed.